8-K: Paragon 28 Reports Record First Quarter Revenue, Reaffirms Full-Year Guidance

Paragon 28 announced record first-quarter revenue of $61.1 million, representing 17.4% growth, and reaffirmed its full-year 2024 revenue guidance.

Summary

• Paragon 28 reported a record consolidated net revenue of $61.1 million for the first quarter of 2024, a 17.4% increase year-over-year.
• U.S. net revenue reached $51.1 million, growing by 13.5% compared to the same period last year.
• International net revenue was a record $10.0 million, showing a 42.2% increase year-over-year.
• The company's gross profit margin was 80.0%, down from 82.9% in the first quarter of 2023.
• Operating expenses increased to $61.8 million, a 21.5% rise from $50.9 million in the first quarter of 2023.
• The net loss for the quarter was $15.2 million, compared to a net loss of $9.1 million in the first quarter of 2023.
• Adjusted EBITDA was a loss of $5.5 million, a decrease of $4.1 million compared to a $1.4 million loss in the first quarter of 2023.
• Paragon 28 reaffirmed its 2024 net revenue guidance of $249 million to $259 million, projecting a 15.1% to 19.7% growth compared to 2023.

Sentiment

Score: 5

Explanation: While the company shows strong revenue growth, the increased net loss and decreased EBITDA temper the positive outlook. The reaffirmation of revenue guidance is a positive sign, but the overall financial performance is mixed.

Positives

• The company experienced strong top-line growth in Q1 2024, with a 17.4% increase in consolidated net revenue.
• International revenue growth was particularly strong, with a 42.2% increase.
• Paragon 28 has a robust product pipeline with 25+ active projects in development.
• The company is seeing increased surgeon activity in the U.S. and internationally.
• The commercial channel continues to expand across all geographies.
• There is a tremendous amount of excitement for the new products introduced this year.

Negatives

• The gross profit margin decreased to 80.0% from 82.9% in the first quarter of 2023.
• Operating expenses increased by 21.5% year-over-year.
• The company reported a net loss of $15.2 million for the quarter, compared to a $9.1 million loss in the same period last year.
• Adjusted EBITDA was a loss of $5.5 million, a decrease of $4.1 million compared to a $1.4 million loss in the first quarter of 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's reliance on non-GAAP measures like Adjusted EBITDA may not be directly comparable to other companies.
• The company's operating expenses are increasing, which is impacting profitability.
• The company is experiencing a net loss and a decrease in Adjusted EBITDA.

Future Outlook

The company reaffirms its 2024 net revenue guidance of $249 million to $259 million, representing 15.1% to 19.7% growth compared to 2023. The company expects normalized seasonality to continue and a stabilized supply chain environment.

Management Comments

• Albert DaCosta, Chairman and Chief Executive Officer, stated that the company is off to a strong start in 2024 and continues to see increased surgeon activity in the U.S. and internationally.
• He also noted that the company's commercial channel continues to expand across all geographies and that there is a tremendous amount of excitement for the new products introduced this year.
• Management believes that their focus on innovation and education across all foot and ankle segments has set them up well for continued sustainable growth.

Industry Context

Paragon 28 operates in the global foot and ankle orthopedic market, which is estimated to have a 7.1% CAGR. The company's growth is outpacing the broader market, indicating a strong position within this niche. The company is focused on innovation and education to drive improved outcomes in this market.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, Paragon 28's 17.4% revenue growth in Q1 2024 suggests a strong performance compared to the estimated 7.1% CAGR of the overall foot and ankle market.
• The company's focus on new product launches and expansion in both the U.S. and international markets aligns with strategies employed by other successful medical device companies.
• However, the decrease in gross profit margin and increased operating expenses may be areas of concern compared to industry benchmarks, requiring further analysis.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased EBITDA, despite the strong revenue growth.
• Employees may be impacted by the ongoing search for a permanent CFO.
• Customers may benefit from the company's continued focus on product innovation and expansion.
• Suppliers may see increased demand due to the company's growth.

Next Steps

• The company will host a conference call on May 8, 2024, to discuss the first quarter 2024 financial results.
• The company will continue to focus on product innovation and expansion in both the U.S. and international markets.
• The company will continue the search for a permanent Chief Financial Officer.

Key Dates

Keywords

medical devices, orthopedics, foot and ankle, revenue growth, financial results, EBITDA, product launch, international sales